Generics Companies Weigh In On Biological Drugs, The Wall Street Journal Reports
The Wall Street Journal: Generics Companies Weigh In On Biological DrugsGeneric drug makers are expecting copies of complex biological drugs to become a multi-billion dollar market in the near future. But a lack of clear regulation, intense scrutiny from makers of the original drugs and the high cost of research may damp their prospects (Mijuk, 1/31). This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
